Jun 17, 2019 / 12:00PM GMT
Operator
Greetings, and welcome to the Ruxolitinib Cream Phase II Data and Vitiligo Webinar and Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host Mike Booth, Head of Investor Relations. Please go ahead, Mike.
Michael Booth - Incyte Corporation - VP of IR
Thank you, Kevin. Good morning, and welcome to our conference call and webcast to discuss vitiligo, the disease, the medical need and the biological rationale for JAK inhibition as a potential therapy. We will also provide some highlights from the presentation of the Phase II data for ruxolitinib cream as a treatment for patients with vitiligo that were presented at the World Congress of Dermatology over the weekend.
The slides used today in today's webcast are available for download on the Investor section of incyte.com as are the full data slides as presented in Milan on Saturday.
I am joined on the call today, not only by Hervé and by Jim Lee, our Head of Inflammation and Autoimmunity Development, but we
Incyte Corp Key Studies Within Its Inflammation And Autoimmunity portfolio Corporate Call Transcript
Jun 17, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers